Impact of polymeric nanoparticles on oral pharmacokinetics: a dose-dependent case study with estradiol.

The present study reports the significance of polymeric nanoparticles in oral drug delivery from pharmacokinetic perspective. Impact of different dose polymeric nanoparticulate formulations on various pharmacokinetic parameters has been reported. All nano-formulations were found to have significant effect on important pharmacokinetic parameters like C(max), T(max), AUC, absolute bioavailability, absorption rate constant (K(a)), elimination rate constant (K(el)), elimination half life (t(1/2)), mean residence time (MRT) and mean absorption time (MAT). Further, drug in polymeric nanoparticles exhibited the flip-flop pharmacokinetics suggesting its slow and sustained release from the polymeric matrix. Together, polymeric nanoparticles hold promise for the oral delivery of molecules having pharmacokinetic hurdles in their delivery approach.

[1]  M. R. Kumar,et al.  Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. , 2006, Drug discovery today.

[2]  Chi H. Lee,et al.  Drug delivery systems for hormone therapy. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[3]  M. D. Hussain,et al.  Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. , 2007, International journal of pharmaceutics.

[4]  Alexander T. Florence,et al.  The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual , 1997, Pharmaceutical Research.

[5]  V. Bhardwaj,et al.  Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[6]  D. McCarthy,et al.  Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose , 1992 .

[7]  U. Bakowsky,et al.  Design of Estradiol Loaded PLGA Nanoparticulate Formulations: A Potential Oral Delivery System for Hormone Therapy , 2006, Pharmaceutical Research.

[8]  D. Faulds,et al.  Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders , 1993, Drugs.

[9]  R. Panchagnula,et al.  Thermoreversible liposomal poloxamer gel for the delivery of paclitaxel: dose proportionality and hematological toxicity studies. , 2008, Die Pharmazie.

[10]  M. R. Kumar,et al.  PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. , 2008, Journal of pharmaceutical sciences.

[11]  Gordon L. Amidon,et al.  Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size , 1996, Pharmaceutical Research.

[12]  Yager Jd,et al.  Molecular Mechanisms of Estrogen Carcinogenesis , 1996 .

[13]  M. R. Kumar,et al.  PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[14]  R. Lobo,et al.  Benefits and risks of estrogen replacement therapy. , 1995, American journal of obstetrics and gynecology.